Mascarenhas Summarizes Therapeutic Standards and Advances in Myelofibrosis Management
February 23rd 2023Dr Mascarenhas discusses established standards of care and ongoing research with JAK inhibitors in patients with myelofibrosis; the available frontline treatment options in this disease; and the nuances of myelofibrosis treatment sequencing.
Read More
EPCORE Pushes CD3 × CD20 Bispecific Antibody Into Next Phase of Exploration in DLBCL
February 15th 2023Advances in the development of bispecific antibodies have demonstrated response rates close to or surpassing those of other agents in development, offering investigators an avenue to pursue phase 3 studies such as EPCORE DLBCL-1 to challenge standard of care with the CD3 × CD20 agent, epcoritamab in diffuse large B-cell lymphoma.
Read More
Small and Reagan Review Tumor Lysis Syndrome Risk Factors and Management Strategies
February 13th 2023Drs Short and Reagan discuss risk factors that can contribute to patients’ likelihood of developing tumor lysis syndrome, preventive measures for patients most at risk, and the clinical implications of standard treatment options for patients with tumor lysis syndrome.
Read More
D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor
February 9th 2023Dr D’Amato discusses research in sarcoma and gastrointestinal stromal tumor, incorporating circulating tumor DNA analysis into routine reevaluation of patients with progressive disease, and the importance of establishing a drug’s clinical profile in non–trial target ethnic populations.
Read More
FDA Approval Insights: Tucatinib and Trastuzumab in HER2+ mCRC
February 6th 2023Dr Strickler discusses the FDA approval of tucatinib plus trastuzumab in metastatic colorectal cancer, key efficacy and safety findings from the MOUNTAINEER trial, and ongoing research seeking to address remaining unmet needs in this population.
Read More
Rosenthal Discusses the Need for Standardized Care in AYA Hodgkin Lymphoma
February 2nd 2023Dr Rosenthal discusses the care of adolescent and young adult patients with Hodgkin lymphoma, the discrepancies between pediatric and adult oncologists that result in differing treatment approaches, and common concerns these patients have as they navigate their diagnosis and treatment alongside other life changes.
Read More
Nair Notes the Benefits of Yoga as a Complementary Therapy in Nonmetastatic Breast Cancer
January 30th 2023Dr Nair discusses a study evaluating the role of yoga as a complementary therapy in patients with breast cancer, how these results emphasize the importance of multidisciplinary breast cancer care, and the potential applications of these findings beyond breast cancer.
Read More
Further Study and Tailored Treatments Remain Unmet Needs in Male Breast Cancer
January 30th 2023Jose Pablo Leone, MD, discusses the distinguishing features of male breast cancer, explains the benefits and limitations of current treatments, and emphasizes the importance of raising awareness about this breast cancer subset to propel further research.
Read More
FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC
January 26th 2023Dr Shore discusses the FDA approval of nadofaragene firadenovec in non–muscle invasive bladder cancer, the benefits of this therapy’s administration method and schedule, and how this agent’s efficacy and safety pave the way for future treatment advances.
Read More
Goetz and Choong Describe the Need for Adjuvant Endocrine Therapy in ER-positive Breast Cancer
January 23rd 2023Drs Goetz and Choong discuss the potential for adjuvant endocrine therapy omission in patients with estrogen receptor–positive breast cancer who have a pathologic complete response to neoadjuvant chemotherapy.
Read More
Experts Contextualize ASH Findings for Clinical Practice
January 23rd 2023Data presented during the 2022 ASH Annual Meeting and Exposition showcased practice-changing updates from several studies across hematologic malignancies. Experts across hematologic cancers were on hand to discuss long-term readouts, the introduction of novel regimens for several diseases, and the impact of new data and trends in care for patients.
Read More
Dy Discusses CEACAM5-Directed and Other Second-Line Treatment Strategies in NSCLC
January 19th 2023Dr Dy discusses the development of CEACAM5-directed antibody-drug conjugates in non–small cell lung cancer, ongoing research with tusamitamab ravtansine, and the potential role of competing docetaxel-based combination strategies in the second-line setting.
Read More
Giacchetti Discusses the Convergence of Chronobiology and Oncologic Care in Breast Cancer
January 16th 2023Dr Giacchetti discusses the findings from a study of patient-selected timing of the daily oral intake of adjuvant hormone therapy and everolimus in breast cancer and how this study highlights the need for further research combining the fields of chronobiology and oncology.
Read More
Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL
January 12th 2023Dr Hilal discusses data with frontline ibrutinib, acalabrutinib, and zanubrutinib in chronic lymphocytic leukemia; remaining uncertainties regarding the use of BTK inhibitors to manage this disease; and how a patient’s minimal residual disease status influences their subsequent treatment options.
Read More
Camidge and Cetnar Consider the Value of Career Scholarship, Leadership, and Mentorship
January 9th 2023In the inaugural episode of ‘How This is Building Me,’ Camidge sits down with Cetnar to discuss the ins-and-outs of defining personal and professional success, perceptions around sought-after accolades and accomplishments, the meaning behind mentoring, and more.
Read More
Oppong Emphasizes How Patient Education Can Lower Breast Cancer Surgery Refusal Rates
January 2nd 2023Dr Oppong discusses findings showing that Black and Hispanic women are more likely than their White counterparts to refuse surgery for nonmetastatic breast cancer, the reasons some patients refuse to undergo surgery, and potential strategies to overcome those objections.
Read More
Rugo Summarizes Developments With Ribociclib and ADCs in HR-Positive Breast Cancer
December 26th 2022Dr Rugo discusses overall survival in the TROPiCS-02 trial, post-progression treatments after ribociclib and endocrine therapy in the MONALEESA-2, MONALEESA-3, and MONALEESA-7 studies, and what the AMALEE trial indicates about optimal doses of ribociclib in hormone receptor–positive breast cancer.
Read More
Expert and Patient Perspectives on Comprehensive Multiple Myeloma Treatment
December 22nd 2022Dr Kumar, Dr Patel, Falbo, and Ahlstrom highlight the importance of community-based discussions regarding adverse effects in multiple myeloma, the benefits of considering the whole treatment course, and subgroup analyses from the MAIA trial.
Read More
Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma
December 19th 2022Dr Blum discusses renal medullary carcinoma, the lack of approved systemic therapy for these patients, and findings showing a correlation between CA-125 levels and increased tumor burden and treatment response in this disease.
Read More
FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
December 15th 2022Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Read More
Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
December 12th 2022Nicholas Acuna discusses research showing that incidence of liver cancer increases over time in people of Mexican descent living in Los Angeles, the “Latino paradox” in health outcomes, and the next steps for this research.
Read More
Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL
December 8th 2022Dr Brody previews mantle cell lymphoma data being presented at the 2022 ASH Annual Meeting and Exposition, including promising data on pirtobrutinib from the BRUIN trial, the potential for CAR T-cell therapy as evidenced in the ZUMA-2 trial, and how immunotherapies such as glofitamab are expanding the treatment paradigm.
Read More
FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
December 5th 2022Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.
Read More